Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. (s)-1-((s)-2-1((-(4-amino-3-chloro-phenyl)-methanoyl)-amino)-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic Acid ((2r,3s)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide
2. (s)-3-((1-((s)-1-((s)-2-((1-(4-amino-3-chlorophenyl)methanoyl)amino)-3,3-dimethyl-butanoyl)pyrrolidin-2yl)methanoyl)amino)-4-oxo-butyric Acid
3. 1-((2s)-2-((4-amino-3-chlorobenzoyl)amino)-3,3-dimethylbutanoyl)-n-((2r,3s)-2- Ethoxy-5-oxo-tetrahydrofuran-3-yl)-l-prolinamide
4. L-prolinamide, N-(4-amino-3-chlorobenzoyl)-3-methyl-l-valyl-n-((1s)-2-carboxy-1-formylethyl)-
5. N-(4-amino-3-chlorobenzoyl)-3-methyl-l-valyl-n-((1s)-2-carboxy-1-formylethyl)-l-prolinamide
6. O-desethyl-belnacasan
7. Vrt 043198
8. Vrt-043198
9. Vx 765
10. Vx-765
11. Vx-765 Hemiketal
12. Vx765
1. Vx-765
2. 273404-37-8
3. Vx765
4. Belnacasan (vx-765)
5. Belnacasan [usan]
6. Belnacasan (vx765)
7. Belnacasan (usan)
8. (s)-1-((s)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-n-((2r,3s)-2-ethoxy-5-oxotetrahydrofuran-3-yl)pyrrolidine-2-carboxamide
9. 851091-96-8
10. Unii-00ole78529
11. Belnacasan(vx-765)
12. Vx-765 (belnacasan)
13. (2s)-1-[(2s)-2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide
14. 00ole78529
15. (2s)-1-[(2s)-2-[(4-amino-3-chlorophenyl)formamido]-3,3-dimethylbutanoyl]-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide
16. 1-((2s)-2-((4-amino-3-chlorobenzoyl)amino)-3,3-dimethylbutanoyl)-n-((2r,3s)-2- Ethoxy-5-oxo-tetrahydrofuran-3-yl)-l-prolinamide
17. L-prolinamide, N-(4-amino-3-chlorobenzoyl)-3-methyl-l-valyl-n-((2r,3s)-2-ethoxytetrahydro-5-oxo-3-furanyl)-
18. N-(4-amino-3-chlorobenzoyl)-3-methyl-l-valyl-n-[(2r,3s)-2-ethoxytetrahydro-5-oxo-3-furanyl]-l-prolinamide
19. Vx 765
20. Belnacasan [usan:inn]
21. Belnacasan [inn]
22. Belnacasan [who-dd]
23. Gtpl9035
24. Schembl3393597
25. Chembl2107819
26. Chebi:188567
27. Dtxsid901017651
28. Hms3884b11
29. Amy24224
30. Zinc3963010
31. Mfcd11100350
32. S2228
33. Akos024464751
34. Ccg-269769
35. Ncgc00183682-09
36. Ncgc00183682-10
37. Ncgc00183682-13
38. (s)-1-((s)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic Acid ((2r,3s)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide
39. As-35159
40. Bcp0726000319
41. Ft-0774330
42. V0176
43. D10416
44. A857663
45. J-523035
46. Q27075000
47. (s)-1-((s)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-n-((2r,3s)-2-ethoxy-5-oxo-tetrahydrofuran-3-yl)pyrrolidine-2-carboxamide;vx-765
48. 1-((2s)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-n-((2r,3s)-2-ethoxy-5-oxooxolan-3-yl)-l-prolinamide
| Molecular Weight | 509.0 g/mol |
|---|---|
| Molecular Formula | C24H33ClN4O6 |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 508.2088625 g/mol |
| Monoisotopic Mass | 508.2088625 g/mol |
| Topological Polar Surface Area | 140 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 818 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in inflammatory disorders (unspecified) and psoriasis and psoriatic disorders.
VX-765 is an orally-absorbed pro-drug of VRT-043198, a potent and selective inhibitor of ICE/caspase-1 sub-family caspases. It has been shown to reduce disease severity and the expression of inflammatory mediators in models of rheumatoid arthritis and skin inflammation, suggesting that it may be useful for treatment of inflammatory diseases.
VX-765 is a potent and selective inhibitor of ICE/caspase-1 sub-family caspases. In preclinical trials, VX-765 was efficiently converted to VRT-043198 when administered orally to mice and inhibited LPS-induced cytokine secretion. The result was a blocking of IL-1beta and IL-18 secretion, with out much effect on the release of several other cytokines, including IL-1{alpha}, tumor necrosis factor-{alpha}, IL-6 and IL-8. There was also no demonstrable activity in cellular models of apoptosis and it did not affect the proliferation of activated primary T-cells or T-cell lines.
ABOUT THIS PAGE
80
PharmaCompass offers a list of Belnacasan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Belnacasan manufacturer or Belnacasan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Belnacasan manufacturer or Belnacasan supplier.
PharmaCompass also assists you with knowing the Belnacasan API Price utilized in the formulation of products. Belnacasan API Price is not always fixed or binding as the Belnacasan Price is obtained through a variety of data sources. The Belnacasan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Belnacasan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Belnacasan, including repackagers and relabelers. The FDA regulates Belnacasan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Belnacasan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Belnacasan supplier is an individual or a company that provides Belnacasan active pharmaceutical ingredient (API) or Belnacasan finished formulations upon request. The Belnacasan suppliers may include Belnacasan API manufacturers, exporters, distributors and traders.
Belnacasan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Belnacasan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Belnacasan GMP manufacturer or Belnacasan GMP API supplier for your needs.
A Belnacasan CoA (Certificate of Analysis) is a formal document that attests to Belnacasan's compliance with Belnacasan specifications and serves as a tool for batch-level quality control.
Belnacasan CoA mostly includes findings from lab analyses of a specific batch. For each Belnacasan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Belnacasan may be tested according to a variety of international standards, such as European Pharmacopoeia (Belnacasan EP), Belnacasan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Belnacasan USP).
